Snyder Nathan A, Kim Adam, Kester Louis, Gale Andrew N, Studer Christian, Hoepfner Dominic, Roggo Silvio, Helliwell Stephen B, Cunningham Kyle W
Department of Biology, Johns Hopkins University, 3400 N. Charles Street, Baltimore, Maryland 21218.
Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland.
G3 (Bethesda). 2019 Mar 7;9(3):829-840. doi: 10.1534/g3.118.200748.
Gene knockout and knockdown strategies have been immensely successful probes of gene function, but small molecule inhibitors (SMIs) of gene products allow much greater time resolution and are particularly useful when the targets are essential for cell replication or survival. SMIs also serve as lead compounds for drug discovery. However, discovery of selective SMIs is costly and inefficient. The action of SMIs can be modeled simply by tagging gene products with an auxin-inducible degron (AID) that triggers rapid ubiquitylation and proteasomal degradation of the tagged protein upon exposure of live cells to auxin. To determine if this approach is broadly effective, we AID-tagged over 750 essential proteins in and observed growth inhibition by low concentrations of auxin in over 66% of cases. Polytopic transmembrane proteins in the plasma membrane, Golgi complex, and endoplasmic reticulum were efficiently depleted if the AID-tag was exposed to cytoplasmic OsTIR1 ubiquitin ligase. The auxin analog 1-napthylacetic acid (NAA) was as potent as auxin on AID-tags, but surprisingly NAA was more potent than auxin at inhibiting target of rapamycin complex 1 (TORC1) function. Auxin also synergized with known SMIs when acting on the same essential protein, indicating that AID-tagged strains can be useful for SMI screening. Auxin synergy, resistance mutations, and cellular assays together suggest the essential GMP/GDP-mannose exchanger in the Golgi complex (Vrg4) as the target of a natural cyclic peptide of unknown function (SDZ 90-215). These findings indicate that AID-tagging can efficiently model the action of SMIs before they are discovered and can facilitate SMI discovery.
基因敲除和敲低策略一直是探究基因功能极为成功的手段,但针对基因产物的小分子抑制剂(SMIs)能实现更高的时间分辨率,在靶点对细胞复制或存活至关重要时尤为有用。SMIs 还可作为药物研发的先导化合物。然而,发现选择性 SMIs 成本高昂且效率低下。SMIs 的作用可通过用生长素诱导降解子(AID)标记基因产物来简单模拟,在活细胞暴露于生长素时,AID 会触发标记蛋白的快速泛素化和蛋白酶体降解。为确定该方法是否具有广泛有效性,我们在酵母中对 750 多种必需蛋白进行了 AID 标记,结果发现超过 66%的情况下低浓度生长素会抑制生长。如果 AID 标签暴露于细胞质中的 OsTIR1 泛素连接酶,质膜、高尔基体复合体和内质网中的多跨膜蛋白会被有效清除。生长素类似物 1-萘乙酸(NAA)对 AID 标签的作用与生长素一样有效,但令人惊讶的是,NAA 在抑制雷帕霉素复合物 1(TORC1)功能方面比生长素更有效。生长素在作用于同一必需蛋白时也能与已知的 SMIs 协同作用,这表明带有 AID 标签的菌株可用于 SMI 筛选。生长素协同作用、抗性突变和细胞分析共同表明,高尔基体复合体中必需的 GMP/GDP-甘露糖交换蛋白(Vrg4)是一种功能未知的天然环肽(SDZ 90-215)的靶点。这些发现表明,AID 标记能够在 SMIs 被发现之前有效地模拟其作用,并有助于 SMI 的发现。